Korea BMS Pharmaceuticals (CEO Lee Hye-young) announced on the 20th that it held a domestic approval meeting for Camzyos, a treatment for 'obstructive hypertrophic cardiomyopathy (oHCM)', on the 19th and introduced its clinical value. Obstructive hypertrophic cardiomyopathy is a severe and rare heart disease in which thickened left ventricular muscle blocks blood flow to the whole body, causing shortness of breath, heart failure, fainting, and sudden cardiac death. Camzyos, developed by Korea BMS Pharmaceuticals, selectively inhibits excessive cross-linking of cardiac myosin and actin, which is the cause of obstructive hypertrophic cardiomyopathy. On May 23, it received approval from the Ministry of Food and Drug Safety